Welcome to our dedicated page for Immunovant SEC filings (Ticker: IMVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunovant, Inc. filings document the formal disclosures of a clinical-stage immunology company developing anti-FcRn product candidates for autoimmune diseases. Recent Form 8-K reports cover quarterly financial results, operating updates, research and development activity, clinical program communications for Graves’ disease and related indications, financing disclosure and other material events.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, executive compensation, equity awards and stockholder voting results. Officer-transition and compensation-related 8-Ks add detail on employment agreements, severance arrangements, consulting services and incentive awards, while the company’s disclosures frame capital structure and governance around its single development-focused operating segment.
IMVT submitted a Rule 144 notice listing proposed sales of common stock tied to restricted stock vesting. The filing lists 17,714 shares associated with three vesting events dated 02/18/2026, 04/01/2026, and 05/18/2026
The entry shows an amount of $678,552.48 alongside the share totals and indicates the submission date 06/26/2026. The filing identifies the securities as restricted stock vesting under a registered plan and names Morgan Stanley Smith Barney LLC as a broker.
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported an open-market sale of 2,634 shares of common stock at $35.39 per share. This transaction was executed to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units.
According to the disclosure, the sale was mandated by the company’s "sell to cover" election and was not a discretionary trade by the officer. Following the transaction, Van Tuyl directly holds 180,597 shares of Immunovant common stock.
Immunovant director Atul Pande exercised stock options and sold shares in a routine, pre-planned transaction. On the same day, he exercised options to acquire 1,500 shares of Common Stock at $8.43 per share and sold 1,500 shares in an open-market transaction at $34.02 per share.
The filing shows he continues to hold 116,731 Common Stock shares directly and 20,000 shares indirectly through a trust, as well as 69,681 remaining stock options after the exercise. The transactions were carried out under a Rule 10b5-1 trading plan adopted on December 26, 2025, indicating they were pre-scheduled rather than discretionary.
Issuer files a Form 144 reporting proposed sale and recent dispositions of Common Stock. The filing lists 6,000 shares tied to an exercise of stock options with a proposed sale date of 06/15/2026. It also reports prior 10b5-1 sales of 6,000 shares on 05/20/2026 for $192,000.
Immunovant, Inc. director Andrew J. Fromkin reported a combination of option exercises and share sales in common stock. On May 28, 2026, he exercised stock options covering 196,601 shares at strike prices ranging from $4.99 to $14.70 per share, converting derivative awards into common shares.
On the same date, he executed open-market sales totaling 221,951 shares of common stock at weighted average prices of $33.56 and $32.64 per share across multiple trades. Following these transactions, he directly holds 74,382 Immunovant common shares, indicating a net reduction in his direct equity position while retaining a meaningful stake.
IMVT (reported by Morgan Stanley Smith Barney LLC Executive Financial Services) filed Form 144 reporting proposed sales of Common shares. The notice lists multiple proposed sale methods and dates, including exercise of options under a registered plan, restricted stock vesting, and an open market purchase.
The filing itemizes individual lot sizes on specific dates, including 16,260, 49,961, 77,181, and other share amounts; these are presented as proposed dispositions rather than aggregated totals.
Immunovant, Inc.’s Chief Operating Officer, Gloria Melanie, reported selling a total of 3,115 shares of common stock on May 20, 2026 in open-market transactions at prices including $30.41, $32.15, and $32.95 per share. A footnote explains these sales were executed solely to cover tax withholding obligations arising from the vesting and settlement of 6,872 restricted stock units granted as part of a larger 109,956 RSU award from November 18, 2024. The issuance’s “sell to cover” structure was chosen by the company and described as a mandated, non-discretionary transaction by the executive. The Form 4 data also reflect a reported direct holding of 244,973 shares of Immunovant common stock after the transactions.
Immunovant, Inc. director Atul Pande reported an option exercise and share sale. On May 20, 2026, he exercised stock options to acquire 6,000 shares of common stock at $8.43 per share and sold 6,000 shares at $32.00 per share.
After these transactions, he directly holds 116,731 common shares and indirectly holds 20,000 shares through a trust. A related footnote states the sale occurred under a pre-arranged Rule 10b5-1 trading plan, indicating the timing was planned in advance.